Dr Bernice Kwong on GVHD: Empower Patients to Call on Doctors for Help
March 28th 2022Bernice Kwong, MD, clinical professor of dermatology, Stanford University, expands on her session about graft-versus-host disease diagnosis and management presented at the 2022 American Academy of Dermatology Annual Meeting, emphasizing the importance of the relationship between patients and doctors.
Watch
What We’re Reading: Epilepsy Drug Approval; Free COVID-19 Testing Ends; EPA Sued
March 28th 2022The FDA approved a drug to treat a rare form of childhood epilepsy; uninsured Americans will no longer have access to free COVID-19 tests; a conservation group is suing the Environmental Protection Agency (EPA) over failure to protect rivers from pollution.
Read More
Underscoring the Diversity Issue in Dermatology: Clinical Trials, Therapeutics, and Care Management
March 28th 2022Clinical trial recruitment and management strategies for diverse populations are among the challenges that affect dermatology care quality and access, according to panelists at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
Read More
High CD47 Expression on HRS Cells Carries Poor Survival Implications in Classical HL
March 27th 2022Retrospective study findings show that CD47 expression on Hodgkin and Reed–Sternberg (HRS) cells varied between patients who had classical Hodgkin lymphoma (HL) and was associated with poor outcomes.
Read More
Dr David Rosmarin on Tailored Biologic Treatments, New Vitiligo Research
March 27th 2022David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center, discusses best practices for choosing biologics, as well as his late-breaking findings on ruxolitinib cream for vitiligo at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
Watch
Dr Robert Sidbury Summarizes Updated Atopic Dermatitis Guidelines at AAD 2022
March 27th 2022Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, sat down to discuss comorbidities newly associated with atopic dermatitis at the 2022 American Academy of Dermatology Annual Meeting.
Watch
Panel Reviews Dietary Triggers, Best Practices for Management of Dermatologic Diseases
March 27th 2022A panel discussion at the 2022 American Academy of Dermatology Annual Meeting addressed the association between food and skin manifestations, as well as dietary triggers and recommendations in the management of a myriad of dermatologic conditions.
Read More
Study Finds Low Natural Antibody Response to Clostridioides difficile
March 27th 2022The presence of antigen-specific and neutralizing antibodies was not associated with Clostridioides difficile infection symptoms, severity, therapy approach, treatment response, or recurrences in a new exploratory study.
Read More
People With HIV More Likely to Develop Hypertension After Starting INSTI-Based ART vs NNRTI
March 26th 2022Adults living with HIV receiving integrase strand transfer inhibitor (INSTI)–based antiretroviral therapy (ART) had a 76% higher incidence of hypertension compared with adults receiving non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Read More
Ruxolitinib Cream Shows Improved Efficacy, Sustained Safety in Vitiligo After Extended Follow-up
March 26th 2022Late-breaking findings at the 2022 American Academy of Dermatology Annual Meeting showed ruxolitinib cream was associated with clinically significant improvement in facial and total body repigmentation vs vehicle in the treatment of adolescent and adult patients with nonsegmental vitiligo over 52 weeks.
Read More
Delving Into Clinical, Epidemiological Differences of Adult, Pediatric Atopic Dermatitis
March 26th 2022Jonathan Silverberg, MD, PhD, MPH, discusses key differences regarding epidemiology, genetic risk factors, and clinical manifestations of pediatric and adult-onset atopic dermatitis, as well as recommended therapeutic approaches for adult patients.
Read More
Dr Art Papier on How Project IMPACT Aims to Reduce Racial Disparities in Dermatology
March 26th 2022The lack of racial representation in dermatology education prompted the launch of Project IMPACT, explained Art Papier, MD, dermatologist, CEO, VisualDx at the 2022 American Academy of Dermatology Annual Meeting.
Watch
Clinical Trial Criteria Should Be “Relevant” to the SCLC Population
March 25th 2022Martin J. Edelman, MD, chair and professor, Department of Hematology/Oncology, and Deputy Cancer Center Director for Clinical Research, Fox Chase Cancer Center, Philadelphia, discusses barriers to clinical trial enrollment for patients with small cell lung cancer.
Read More
Record High Pediatric Parainfluenza Virus Incidence in Finland
March 25th 2022Monthly parainfluenza virus incidence rates were nearly 6 times higher in September 2021 vs the second highest reported monthly incidence rates among children 4 years and younger in Finland in the last decade, following lifting of COVID-19–related restrictions.
Read More
Care for Migraine Insufficient in Germany, Online Survey Finds
March 25th 2022An online survey of migraineurs in Germany aimed to evaluate their most pressing unmet needs, with data collected on socioeconomic background, medical care experience, acute medication use, and migraine prophylaxis use and experience.
Read More
Autonomic Dysfunction Could Be Associated With Idiopathic Hypersomnia, According to Review
March 25th 2022A review indicated that there may be an association between autonomic dysfunction and idiopathic hypersomnia, as well as between sleep disturbances and postural orthostatic tachycardia syndrome.
Read More
Obesity Increases Risk of MM Precursor, While Weight Loss Indicates Risk of Cancer Diagnosis
March 25th 2022Weight and changes in it can indicate implications for cancer risk and cancer diagnosis, according to 2 abstracts being presented at the American Association for Cancer Research Annual Meeting.
Read More
Meta-Analysis Finds Dupilumab Most Effective Biologic for CRS With Nasal Polyps
March 25th 2022A comparison of type 2 biologics indicated for the treatment of chronic rhinosinusitis with nasal polyps identified dupilumab as the most effective drug in decreasing nasal polyp score and nasal congestion severity, whereas benralizumab was least effective.
Read More